<DOC>
	<DOCNO>NCT01253902</DOCNO>
	<brief_summary>This study evaluate ocular surface tolerability prostaglandin analogues bimatoprost ophthalmic solution 0.01 % ( Lumigan® 0.01 % ) , travoprost ophthalmic solution 0.004 % ( Travatan Z® ) latanoprost ophthalmic solution 0.005 % ( Xalatan® ) patient previously treat Xalatan® open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Ocular Surface Tolerability Study Prostaglandin Analogues Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis ocular hypertension openangle glaucoma least 1 eye require treatment antiglaucoma/ocular hypertensive medication Best correct visual acuity score 20/100 good eye Females birth control pill must type pill dose least 3 month Use Lumigan® 0.01 % /Lumigan® RC , Lumigan® , Travatan® Travatan Z® within 6 month History active ocular infection/inflammation ( eg , uveitis ) Punctal plug use Required use ocular medication study study medication ( intermittent use certain type artificial tear acceptable ) Intraocular surgery glaucoma laser surgery study eye ( ) within 3 month History corneal refractive laser surgery ( eg , LASIK , LASEK ) study eye ( ) Planned contact lens wear study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>